Abstract:Background Adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is an autosomal dominant primary microgliopathy caused by kinase loss‐of‐function mutations in the CSF1 receptor (CSF1R). The cardinal features of ALSP include demyelination, axonopathy, and symptoms ranging from frontal temporal dementia‐like behavior, movement disorders, epilepsy, and psychiatric manifestations. Many of these hallmarks further resemble Nasu‐Hakola disease, another rare leukoencephalopathy associated with homozygous mutations in triggering receptor expressed on myeloid cells 2 (TREM2) or its tyrosine kinase binding adaptor (TYROBP) which result in complete loss‐of‐function of TREM2 or its signaling partner DAP12. Following binding to its cognate ligands, IL‐34 or CSF‐1, CSF1R dimerization initiates a signaling cascade both through its kinase domain and through DAP12, which together activate SYK to promote myeloid cell survival, proliferation, and morphological changes. While analogous to CSF1R in cellular expression and interaction with DAP12, TREM2 lacks intrinsic signaling capacity and therefore requires DAP12 to translate extracellular damage‐associated cues and orchestrate a constellation of intracellular and functional responses which phenocopy CSF1R activation. Accordingly, we hypothesize TREM2 activation may rescue CSF1R loss‐of‐function and ameliorate ALSP‐associated pathology. Methods To test whether TREM2 gain‐of‐function could compensate for CSF1R loss‐of‐function, we developed multiple approaches to model ALSP in human myeloid cells by CSF‐1/IL‐34 depletion or CSF1R kinase inhibition using PLX‐5622 and explored functional intervention via a human TREM2 agonistic antibody, VGL101, currently in Phase‐1 clinical development. Rescue for CSF1R was quantified using a combination of live‐cell morphology captured via automated longitudinal microscopy, viability monitored by ATP Cell‐Titer Glo, and apoptosis quantified by Caspase‐3/7 fluorogenic‐imaging. Results In vitro phospho‐SYK profiling of VGL101 in iPSC‐derived microglia is consistent with its agonist profile (EC50: 0.77 ± 0.08 nM), while the absence of pSYK induction in TREM2‐knockout microglia demonstrates exquisite on‐target selectively. In both CSF‐1/IL‐34 depletion and CSF1R kinase inhibition paradigms of ALSP, VGL101 demonstrated full rescue of microglial and monocyte‐derived macrophage viability, inhibited apoptosis, and promoted morphological changes resembling intact CSF1R activation. Conclusion Collectively, our studies support the hypothesis that TREM2 agonism can compensate for CSF1R dysfunction and highlight the therapeutic potential for treating ALSP with TREM2 agonism via VGL101 passive immunotherapy.

Trem2 Enhances Demyelination in the Csf1r+/− Mouse Model of Leukoencephalopathy

Identification and Validation of TREM2 in Intracranial Aneurysms

TREM2 Activation Attenuates Neuroinflammation and Neuronal Apoptosis Via PI3K/Akt Pathway after Intracerebral Hemorrhage in Mice.

Distinct myeloid population phenotypes dependent on TREM2 expression levels shape the pathology of traumatic versus demyelinating CNS disorders

Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Interacts with Colony-Stimulating Factor 1 Receptor (CSF1R) but is Not Necessary for CSF1/CSF1R-Mediated Microglial Survival.

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models

TREM2 Regulates Microglial Cholesterol Metabolism Upon Chronic Phagocytic Challenge

Loss of TREM2 diminishes CAA despite an overall increase of amyloid load in Tg-SwDI mice

Soluble TREM2 Induces Inflammatory Responses and Enhances Microglial Survival

Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease

Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimers Disease and Multiple Sclerosis

Trem2-deficiency aggravates and accelerates age-related myelin degeneration

VGL101 Rescues CSF1R Dysfunction in Human Microglia And Macrophages: Evaluation of In Vitro Trem2 Agonism in Models Of A CSF1R‐Dependent Leukodystrophy

TREM2 alleviates white matter injury after traumatic brain injury in mice might be mediated by regulation of DHCR24/LXR pathway in microglia

TREM2 Deficiency Inhibits Microglial Activation and Aggravates Demyelinating Injury in Neuromyelitis Optica Spectrum Disorder

Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 and Triggering Receptor Expressed on Myeloid Cells-Like Transcript 2 in Microglia Activation.

TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism

Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis

TREM2 improves neurological dysfunction and attenuates neuroinflammation, TLR signaling and neuronal apoptosis in the acute phase of intracerebral hemorrhage

TREM2 overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway

TREM2 deficiency impairs the energy metabolism of Schwann cells and exacerbates peripheral neurological deficits